ARGENX SE-ADR (NASDAQ:ARGX) has been given an average broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus target price of $29.67 for the company, according to Zacks. Zacks has also given ARGENX SE-ADR an industry rank of 103 out of 265 based on the ratings given to its competitors.

ARGX has been the topic of a number of recent analyst reports. Cowen and Company initiated coverage on ARGENX SE-ADR in a research report on Monday, June 12th. They set an “outperform” rating on the stock. JMP Securities initiated coverage on ARGENX SE-ADR in a research report on Monday, June 12th. They set an “outperform” rating and a $33.00 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating on shares of ARGENX SE-ADR in a research report on Monday, June 12th.

ARGENX SE-ADR (ARGX) traded up 2.40% on Thursday, reaching $25.59. The company’s stock had a trading volume of 22,063 shares. ARGENX SE-ADR has a 52-week low of $17.33 and a 52-week high of $25.94. The firm has a 50-day moving average price of $21.37 and a 200 day moving average price of $20.95. The firm’s market capitalization is $688.14 million.

Institutional investors have recently made changes to their positions in the company. Nicholas Investment Partners LP acquired a new stake in shares of ARGENX SE-ADR during the second quarter worth $236,000. DAFNA Capital Management LLC purchased a new position in shares of ARGENX SE-ADR during the second quarter valued at $848,000. Tekla Capital Management LLC purchased a new position in shares of ARGENX SE-ADR during the second quarter valued at $1,591,000. AWM Investment Company Inc. purchased a new position in shares of ARGENX SE-ADR during the second quarter valued at $2,121,000. Finally, Jennison Associates LLC purchased a new position in shares of ARGENX SE-ADR during the second quarter valued at $2,657,000. 22.74% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/05/analysts-set-29-67-price-target-for-argenx-se-adr-argx.html.

ARGENX SE-ADR Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Get a free copy of the Zacks research report on ARGENX SE-ADR (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related companies with MarketBeat.com's FREE daily email newsletter.